ALISON ONEILL - 01 Mar 2020 Form 4 Insider Report for Surface Oncology, Inc.

Role: Chief Medical Officer
Signature: /s/ Jessica Fees, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Mar 2020
Net transactions value: -$90,335
Form type: 4
Filing time: 14 Jan 2022, 19:30:16 UTC
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SURF	Common Stock	Award	$0	+45,000		$0.000000	45,000	01 Mar 2020	Direct	F1
transaction	SURF	Common Stock	Sale	$90,335	-14,809	-33%	$6.10	30,191	21 Jul 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in full on the date 18 months after January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such date.
F2	Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units.

Content

The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in full on the date 18 months after January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such date.

Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units.